|Been trying to gauge what IMMU will present at SABCS this year given TNBC data has already been published, new trials with PARP inhibitors are still too immature to present. What on earth could move mountains?|
Hoping this crack(pipe) team can help me dig up info to corroborate my suspicions, but from the looks of it, we have never yet presented OS data on HR+/HER2- patients from the Phase 1/2 data.
Bardia presented data on 54 patients over a year ago at ASCO highlighting PFS & ORR for IMMU-132 in late stage disease, and at that time 70% of patients were still being monitored.
Can someone help confirm that the OS data has never been published, or am I missing something?
All I can find is they aligned with the FDA on final scope for Ph3, but no publishing of OS data.
From the math of it, this number could be a doozy worthy of SABCS presentation...
Results: Fifty-four pts with HR+/HER2- mBC (all female; median age 54 yrs, range 33-79) were accrued between 2/2015 and 6/2017 (has data been published on OS since 6/2017?)
Take a midpoint of this timeframe, say April 2016, Bardia should have published OS data from this cohort at ASCO theoretically, no?
Keep me on my toes and point out the OS data from this cohort my friends, otherwise, let's see what Santa has in store for us this coming December.